Jun 23, 2025 | Business, Data Analytics, Diabetes, Disease Area Trends
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....
Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends, Heart Disease
When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the pharmaceutical industry is playing an ever smaller role. New blockbuster drugs are the lifeblood of pharmaceutical companies. Traditionally, they...
Jun 23, 2025 | Business, Industry Trends
M&A mania is here. Unprecedented deal values for mergers and acquisitions dominated in 2014. Worldwide M&A was up 47% since 2013 with 95 deals valued greater than $5 billion, as reported by Reuters. Most deals were transacted in the energy,...
Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...
Jun 23, 2025 | Case Study, Case Study Forecasting
A multinational pharmaceutical firm asked Ozmosi to provide forecasts to assess the market impact of delays in delivering new formulation and packaging for an existing product. A planned reformulation seen as necessary to preserving market share had been delayed for...